Description
Release form
Maxikold. Tablets.
Packing
In a blister pack of 10 tablets. In the package 1 blister.
Indications
Symptomatic treatment of infectious and inflammatory diseases (including influenza and other acute respiratory viral infections (SARS)), accompanied by fever, chills, nasal congestion, headache, pain in the bones and muscles, sore throat and sinuses .
Use during pregnancy and lactation
Caution is advised during pregnancy and lactation.
Composition
1 tablet contains:
Active Ingredients
Paracetamol 500 mg.
Phenylephrine hydrochloride 10 mg.
Ascorbic acid 30 mg.
Excipients
Croscarmellose sodium 28 mg,
calcium hydrogen phosphate 97.92 mg,
ethyl cellulose 0.2 mg,
hyprolysis (hydroxypropyl cellulose (Klucel EF)) 19.7 mg,
magnesium stearate 7 mg, scalc 7 mg, srd dye sun sunset yellow (E 110) 0.18 mg to obtain a core weighing 700 mg.
Shell composition
Hypromellose (hydroxypropyl methylcellulose) 13.2 mg,
hyprolysis (hydroxypropyl cellulose (Klucel EF)) 7.701 mg,
talc 6.3 mg,
titanium dioxide 2.75 mg,
dye 0.049 yellow (yellow) mg to obtain a coated tablet weighing 730 mg.
Dosage and administration
Inside, before meals or 1 2 hours after eating, drinking plenty of fluids.
Adults and children over 12 years of age (body weight over 40 kg): 1-2 tablets every 4-6 hours. Multiplicity of admission is not more than 4 times a day with an interval of at least 4 hours.
For children aged 9 to 12 years (body weight over 30 kg): 1 tablet every 4-6 hours. Multiplicity of admission is not more than 4 times a day with an interval of at least 4 hours.
The drug is not recommended for use for more than 5 days as an anesthetic and 3 days as an antipyretic without consulting a doctor. If symptoms persist, consult a doctor.
Do not exceed the indicated dose.
Side effects
Allergic reactions (skin rash, skin hyperemia, urticaria, angioedema) are possible.
Paracetamol: hematopoiesis (anemia, thrombocytopenia, methemoglobinemia).
Phenylephrine: headache, nausea or vomiting of angina pectoris, bradycardia, dyspnea, increase or decrease in blood pressure, palpitations, tachycardia, ventricular arrhythmia (especially when used in high doses), irritability, motor anxiety, allergic reactions.
Ascorbic acid: can cause irritation of the gastrointestinal mucosa, with prolonged use of large doses – nausea, vomiting, diarrhea, hyperacid gastritis, ulceration of the gastrointestinal mucosa, decreased capillary permeability (possibly worsening trophic tissue, increased blood pressure, hypercoagulation, development of microangiopathies). It is also possible the occurrence of thrombocytosis, hyperprothrombinemia, erythropenia, neutrophilic leukocytosis, hypokalemia, glucosuria, inhibition of the function of the insular apparatus of the pancreas.
With prolonged use at doses significantly higher than recommended, the likelihood of impaired renal function (moderate pollakiuria, hyperoxaluria, nephrolithiasis, damage to the glomerular apparatus of the kidneys), increased CNS excitability, headache, insomnia.
In case of adverse reactions, consult a doctor.
Drug Interaction
The drug enhances the effects of monoamine oxidase inhibitors, sedatives, ethanol.
The risk of developing hepatotoxic action of paracetamol increases with simultaneous intake of ethanol, hepatotoxic drugs, inducers of enzymes of microsomal oxidation in the liver (phenytoin, barbiturates, rifampicin, phenylbutazone, tricyclic antidepressants).
The concomitant use of paracetamol in high doses increases the effect of anticoagulant drugs (reducing the synthesis of procoagulant factors in the liver). Paracetamol reduces the effectiveness of uricosuric drugs.
Prolonged use of barbiturates reduces the effectiveness of paracetamol. Metoclopramide and domperidone increase, and cholestyramine reduces the suction rate of paracetamol. Inhibitors of microsomal oxidation enzymes (including cimetidine) reduce the risk of hepatotoxic action of paracetamol.
Concomitant use of ethanol and paracetamol promotes the development of acute pancreatitis. Prolonged co-administration of paracetamol and non-steroidal anti-inflammatory drugs increases the risk of analgesic nephropathy and renal papillary necrosis, and the onset of end-stage renal failure.
Concurrent long-term administration of high-dose paracetamol and salicylates increases the risk of kidney or bladder cancer. Diflunisal increases the plasma concentration of paracetamol by 50% – the risk of hepatotoxicity. Myelotoxic drugs increase the manifestations of hematotoxicity of paracetamol.
Phenylephrine reduces the antihypertensive effect of diuretics and antihypertensive drugs (including methyldopa, mecamylamine, guanadrel, guanethidine), reduces the anti-anginal effect of nitrates.
Phenothiazines, alpha-blockers (phentolamine), furosemide and other diuretics reduce the hypertensive effect of pheniramine. Inhibitors of monoamine oxidase (including furazolidone, procarbazine, selegiline), oxytocin, ergot alkaloids, tricyclic antidepressants, methylphenidate, adrenostimulators enhance the vasoconstrictor effect and arrhythmogenicity of phenylephrine, on phonylephrine. Ergometrine, ergotamine, methylergometrine, oxytocin, doxapram increase the severity of the vasoconstrictor effect of feniramine.
Inhalation anesthetics (including chloroform, enflurane, halothane, isoflurane, methoxyflurane) increase the risk of severe atrial and ventricular arrhythmias. Thyroid hormones increase (mutually) the effect of phenylephrine and the associated risk of coronary insufficiency (especially in coronary atherosclerosis).
Ascorbic acid increases the concentration in the blood of benzylpenicillin and tetracyclines, reduces the effectiveness of heparin and indirect anticoagulants, increases the total clearance of ethanol, which in turn reduces the concentration of ascorbic acid in the body, reduces the therapeutic effect of non-therapeutic drugs and tricyclic antidepressants.
When used with acetylsalicylic acid, urinary excretion of ascorbic acid increases and acetylsalicylic acid is reduced. Acetylsalicylic acid, oral contraceptives, fresh juices and alkaline drink reduce the absorption and absorption of ascorbic acid.
Ascorbic acid improves absorption in the gut of iron preparations increases the risk of crystalluria when treated with short-acting salicylates and sulfanilamides, slows the elimination of kidneys by acids, increases the excretion of drugs having an alkaline reaction (including alkaloids), contra reduces the chronotropic effect of isoprenaline. Prolonged use or high doses may interfere with the interaction of disulfiram and ethanol, in high doses increases excretion of mexiletine by the kidneys.
Quinoline drugs, calcium chloride, salicylates, glucocorticoids depletion of ascorbic acid in long-term use. Barbiturates and primidone increase the excretion of ascorbic acid in the urine.
Storage conditions
In a dry place at a temperature not exceeding 25 ° C. Keep out of the reach of children
Expiration
2 years.
Deystvuyuschee substances
Paracetamol, phenylephrine, ascorbic acid
pharmacy leave terms without a prescription
dosage form
dosage form
tablets
Pharmstandard-Leksredstva, Russia
